GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
https://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.png00https://siii-clinical.com/wp-content/uploads/2021/09/Untitled-1.png2024-10-10 00:10:422024-10-10 00:10:42Zantac’s Developer Settles Lawsuits Claiming Cancer Link
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.